LEADER 05718nam 22005775 450 001 9910254651303321 005 20200701041353.0 010 $a981-10-3262-9 024 7 $a10.1007/978-981-10-3262-2 035 $a(CKB)3710000001364715 035 $a(DE-He213)978-981-10-3262-2 035 $a(MiAaPQ)EBC4855554 035 $a(PPN)201469936 035 $a(EXLCZ)993710000001364715 100 $a20170505d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDecision Making in a World of Comparative Effectiveness Research$b[electronic resource] $eA Practical Guide /$fedited by Howard G. Birnbaum, Paul E. Greenberg 205 $a1st ed. 2017. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Adis,$d2017. 215 $a1 online resource (XVI, 289 p. 18 illus., 7 illus. in color.) 311 $a981-10-3261-0 320 $aIncludes bibliographical references at the end of each chapters. 327 $aI. Introduction -- 1. Introducing Decision Making in a World of Comparative Effectiveness Research -- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies -- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers -- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney -- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company -- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies -- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation -- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER -- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers -- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making? -- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations -- 10. Decision Making by Public Payers -- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials -- 12. Policy Considerations: Ex-U.S. Payers and Regulators -- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective -- 16. Legal Considerations in a World of CER -- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data -- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines -- 18. Challenges in Developing and Assessing CER for Medical Technology -- 19. Evidence Generation Using Big Data: Challenges and Opportunities -- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later -- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry. 330 $aIn the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufactures), government (both public and private payers), as well as decision makers of all levels, both in the US and globally. . 606 $aPharmacy management 606 $aHealth economics 606 $aStatistics  606 $aPharmaceutical technology 606 $aPharmacoeconomics and Health Outcomes$3https://scigraph.springernature.com/ontologies/product-market-codes/H69020 606 $aHealth Economics$3https://scigraph.springernature.com/ontologies/product-market-codes/W35000 606 $aStatistics for Life Sciences, Medicine, Health Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/S17030 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 615 0$aPharmacy management. 615 0$aHealth economics. 615 0$aStatistics . 615 0$aPharmaceutical technology. 615 14$aPharmacoeconomics and Health Outcomes. 615 24$aHealth Economics. 615 24$aStatistics for Life Sciences, Medicine, Health Sciences. 615 24$aPharmaceutical Sciences/Technology. 676 $a615.1 702 $aBirnbaum$b Howard G$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGreenberg$b Paul E$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910254651303321 996 $aDecision Making in a World of Comparative Effectiveness Research$91556177 997 $aUNINA